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Treatment of Elderly Non–small Cell Lung Cancer Patients
with Three Different Schedules of Weekly Paclitaxel in
Combination with Carboplatin: Subanalysis of a
Randomized Trial
Suresh Ramalingam, MD,* John Barstis, MD,† Michael C. Perry, MD,‡ Renato V. La Rocca, MD,§
Sreenivasa R. Nattam, MD, David Rinaldi, MD,¶ Ray Clark, MD,# Glenn M. Mills, MD,** and
Chandra P. Belani, MD*
Background: Administration of paclitaxel on a weekly schedule in
combination with carboplatin is associated with a lower incidence of
neuropathy and myelosuppression. The authors conducted subgroup
analysis of their randomized phase II study of three different
schedules of weekly paclitaxel with carboplatin to determine the
efficacy of each regimen in elderly patients (aged  70 years) with
advanced non–small-cell lung cancer (NSCLC).
Methods: Patients with advanced NSCLC were randomized to one
of three different weekly paclitaxel/carboplatin regimens. After four
cycles of chemotherapy, those with objective response or stable
disease were randomized to weekly paclitaxel or observation as
maintenance therapy. Four hundred three patients were enrolled in
the study, of whom 111 (28%) were aged 70 years or older.
Results: The treatment regimen of weekly paclitaxel (100 mg/m2
for 3 of 4 weeks) and carboplatin (area under the curve  6
mg/ml/min once every 4 weeks) (arm 1) was associated with the best
therapeutic index overall. The median survival and 1-year survival
rates were 11.3 months and 50% for patients in the70 years cohort
versus 11.2 months and 46% for the 70 years cohort in arm 1.
Efficacy results were comparable between the two groups in the
other arms as well. Grade 4 neutropenia and febrile neutropenia
occurred in 13.6% and 2.3% in the 70 years cohort compared with
4.5% and 1.1% in the 70 years cohort in arm 1.
Conclusion: The weekly regimen of paclitaxel administered in
combination with carboplatin is tolerated well by elderly NSCLC
patients and has comparable efficacy with younger patients.
Key Words: Age-specific subanalysis, Carboplatin, Combination
therapy, Elderly, Non–small-cell lung cancer, Weekly paclitaxel.
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Systemic chemotherapy improves both survival and qualityof life for patients with advanced non–small cell lung
cancer (NSCLC).1 A platinum-based two-drug combination
constitutes the current standard of care for the treatment of
patients with advanced NSCLC who have a good perfor-
mance status (PS). However, the efficacy of platinum-based
doublets in elderly (aged  70 years) patients with advanced
NSCLC has not been studied extensively. Although elderly
patients account for approximately 30 to 40% of all cases of
NSCLC, they have not been represented in a proportionate
manner in clinical trials.2 Therefore, the safety and efficacy
data generated from randomized clinical trials cannot be
generalized to elderly NSCLC patients. The choice of che-
motherapy regimen for elderly NSCLC patients is influenced
by both physician- and patient-related factors. Perception of
higher toxicity and lower efficacy in elderly patients by both
the treating physician and the patient may result in subopti-
mal therapeutic selections. It is therefore important that
elderly patients are adequately represented in clinical trials,
and it is also important to conduct prospective studies exclu-
sively in elderly patients. Treatment of elderly patients with
systemic chemotherapy may be limited by various factors
such as comorbid illnesses, age-related changes in organ
function, and concerns regarding increased toxicity. It is
therefore important that elderly patients are adequately rep-
resented in clinical trials and that we also conduct prospective
elderly-specific studies.
Randomized clinical trials have established the utility
of single-agent chemotherapy in elderly patients.3–5 The El-
derly Lung Cancer Vinorelbine Study compared treatment
with vinorelbine plus best supportive care to best supportive
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care alone.3 Although the study did not complete its planned
accrual, both survival and quality-of-life benefits were noted
for the elderly patients treated with chemotherapy. The Multi-
center Italian Lung Cancer Elderly Study compared single-
agent therapy with vinorelbine or gemcitabine with the com-
bination of the same drugs.4 There was no added benefit when
the two drugs were given in combination compared with
single-agent therapy alone. However, toxicity was more pro-
nounced with the combination regimen. Because platinum-
based doublet regimens are superior to single-agent therapy
with either a platinum compound or a novel agent alone,6–9
there is a need to evaluate platinum-based combination reg-
imens in elderly patients.
The combination of carboplatin and paclitaxel is a
commonly used regimen for the treatment of patients with
advanced NSCLC. The principal toxicities associated with
this regimen are myelosuppression and neuropathy.10 Weekly
administration of paclitaxel, however, is associated with a
lower incidence of neuropathy and hematologic toxicity.
Another potential advantage to administration of paclitaxel at
frequent, low dose is its ability to inhibit tumor neoangiogen-
esis.11 We conducted a randomized phase II study to evaluate
the tolerability and efficacy of weekly administration of
paclitaxel in combination with carboplatin for the treatment
of patients with advanced NSCLC.12 The results of this study
were reported earlier and demonstrated that a regimen of
carboplatin given every 4 weeks in combination with weekly
paclitaxel for 3 of 4 weeks was associated with the best
therapeutic index among three different weekly schedules.
The median survival was 11.3 months and the 1-year survival
rate was 47% with this regimen. The incidence of grade 3/4
neuropathy was 5%, compared with 12 to 18% noted with the
3-weekly regimen of carboplatin and paclitaxel. The impres-
sive safety profile of the weekly schedule makes this regimen
worthy of evaluation for the treatment of elderly NSCLC
patients. Therefore, we performed a subset analysis of our
randomized study to determine the efficacy and toxicity of the
weekly schedules of paclitaxel in combination with carbopla-
tin for elderly patients with advanced or metastatic NSCLC.
PATIENTS AND METHODS
Eligibility criteria were as follows: age 18 years or
older; histologically or cytologically confirmed stage IIIB
(pleural/pericardial effusion) or IV NSCLC; presence of mea-
surable disease; Eastern Cooperative Oncology Group
(ECOG) PS of less than or equal to 2; estimated life expect-
ancy of 12 weeks or more; and adequate hematologic, renal,
and hepatic function at baseline.
The treatment plan for this study included maintenance
single-agent paclitaxel after four cycles of initial combination
chemotherapy for patients who experienced an objective
response or stable disease with initial therapy. The protocol
was approved by institutional review boards with jurisdiction
over specific sites that registered patients onto the study. Each
patient gave written informed consent before enrollment.
The treatment scheme was as follows: arm 1, paclitaxel
100 mg/m2 weekly for 3 of 4 weeks with carboplatin area
under the curve (AUC)  6 mg/ml/min on day 1 of each
4-week cycle for a total of four cycles; arm 2, paclitaxel (100
mg/m2) and carboplatin (AUC  2 mg/ml/min) weekly for 3
of 4 weeks of each of four cycles; and arm 3, paclitaxel (150
mg/m2 for cycle 1 and 100 mg/m2 for cycle 2) and carbopla-
tin (AUC 2 mg/ml/min) weekly for 6 of 8 weeks for a total
of two cycles. Premedication administered 30 to 60 minutes
before paclitaxel consisted of dexamethasone 20 mg intrave-
nously (IV), diphenhydramine 50 mg IV, and a histamine 2
blocker (such as cimetidine 300 mg or ranitidine 50 mg IV).
After four cycles of therapy, patients who experienced com-
plete response, partial response, or stable disease were ran-
domized to the maintenance phase of therapy with weekly
paclitaxel or observation. Each cycle of maintenance chemo-
therapy consisted of paclitaxel 70 mg/m2 weekly for 3 of 4
weeks.
To evaluate the outcome for elderly NSCLC patients
who participated in the study, we compared the baseline
characteristics and toxicity and efficacy data for patients aged
70 years or older with those younger than 70 years of age.
Subgroup analyses were based on stratification by disease
stage (IIIB versus IV) and ECOG PS (0–1 or 2). Toxicity was
graded by the National Cancer Institute Common Toxicity
Criteria Version 2.0 and responses were assessed by World
Health Organization criteria.
RESULTS
This multicenter study was conducted between May of
1998 and June of 2000. A total of 403 patients were enrolled,
and 390 were assessable. Patient baseline characteristics for
the initial therapy phase were comparable across treatment
arms and age groups (Table 1). Of the 403 enrolled patients,
111 (28%) were aged 70 years or older.
The median age for the elderly subset of patients in the
three arms of the study was 74 years. The median age for
patients younger than 70 years in the three arms of the study
were 59, 60, and 59 years, respectively. There was a slightly
higher male-to-female ratio for elderly patients enrolled in
arm 2 compared with other arms of the study. There was a
higher proportion of elderly patients with ECOG PS 2 in arm
2 (29%) compared with the other arms of the study.
Efficacy
The overall results of the study demonstrated that arm
1 was associated with the best therapeutic index. The re-
sponse rate was 32% for patients in this arm, and the median
survival was 11.3 months. There were 44 patients in the
TABLE 1. Baseline Characteristics
Arm 1 Arm 2 Arm 3
>70 Yr <70 Yr >70 Yr <70 Yr >70 Yr <70 Yr
No. 44 88 34 96 33 95
Median age (yr) 74 59 74 60 74 59
Male/female (%) 57/43 60/40 76/24 60/40 64/36 60/40
Stage IIIB/IV (%) 25/75 23/77 21/79 24/76 27/73 20/80
ECOG PS 2 (%) 11 16 29 8 21 13
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elderly cohort on this arm compared with 88 patients who
were in the 70 years cohort. The median survivals for the
70 years and 70 years cohorts were 11.3 months and 11.2
months, respectively, on arm 1. Time to progression was 6.9
months and 7.2 months, respectively, for the elderly and
younger patients. The 1-year survival rates were also compa-
rable. Arm 2 was associated with the least favorable outcome,
with median survival duration of 6 months and 7.7 months in
the elderly and younger groups, respectively. For the 33
patients who were aged 70 years or older in arm 3, the median
survival was 14.4 months compared with 9.1 in the younger
group (Table 2).
Toxicity
There was no evidence of excessive toxicity for elderly
patients treated with the combination regimens, with the
exception of grade 4 neutropenia (Table 3). The incidence of
grade 4 neutropenia in the elderly cohort was 13.6% and
12.1% in arms 1 and 3 versus 4.5% and 9.5%, respectively,
for the70 years age group. Febrile neutropenia rates for the
70 years cohort were 1.1%, 1.0%, and 5.3% for arms 1, 2,
and 3, respectively, versus 2.3%, 2.9%, and 3.0% for those in
the 70 years cohort. Grade 3/4 thrombocytopenia occurred
in 2.3% of patients in the70 year cohort and was noted only
in arm 1. There were no major differences in the nonhema-
tologic toxicity profiles between the two cohorts in arm 1
(Table 4). Neuropathy was more common for patients treated
in arm 3, although there was no difference between the two
age cohorts in all three arms of the study. There was one
episode of grade 4 peripheral neuropathy in arm 3 in the
younger group.
DISCUSSION
Platinum-based chemotherapy has become the corner-
stone of therapy for patients with advanced NSCLC. How-
ever, the efficacy of platinum-based chemotherapy has not
been evaluated adequately in elderly patients by prospective
trials. To date, the only prospectively planned evaluation of
platinum-based chemotherapy in elderly patients was con-
ducted in the CALGB 9730 trial.6 This was a randomized
comparison between paclitaxel administered alone or in com-
bination with carboplatin for patients with advanced NSCLC.
Approximately 27% of the patients who participated in this
study were older than 70 years. The study design allowed for
stratification of patients by age (70 years versus 70
years). The response rate and survival rates noted in the
elderly patients were comparable to those of younger patients
in this study. There was a higher incidence of leukopenia,
sepsis, and febrile neutropenia in elderly patients. The other
toxicities were comparable to that of younger patients. How-
ever, because of the smaller number of elderly patients in the
study, these observations did not reach statistical significance.
Similar observations have been made by retrospective anal-
yses of outcome for elderly patients from randomized trials
conducted in advanced NSCLC.13,14 Langer et al. conducted
a subset analysis of patients who participated in the ECOG
1594 trial that evaluated four different chemotherapeutic
regimens for the treatment of advanced NSCLC.14 Of the
1207 patients enrolled to the study, 227 (20%) were older
than 70 years and nine patients (1%) were older than 80
years. Delivery of chemotherapy was comparable for the
younger than 70 and 70 years or older age groups. Approx-
imately 34% of the younger patients completed the planned
six cycles of chemotherapy, compared with 30% of the
elderly cohort. The median survival duration was 8.15 and
8.25 months for the younger and elderly cohorts, respec-
tively. On the basis of these results, the authors concluded
that elderly patients with a good performance status (ECOG
PS 0/1) tolerate and benefit from systemic chemotherapy
similar to younger patients.
To improve the overall tolerability of the taxanes in the
elderly patients, weekly schedules of both paclitaxel and
docetaxel have been developed.15,16 Promising efficacy with-
out an appreciable increase in toxicity was noted from these
studies. In a phase II study, Fidias et al. treated elderly
NSCLC patients with a weekly dose of paclitaxel (90 mg/m2
for 6 of 8 weeks).15 A promising response rate (23%) and
median survival (10.2 months) were noted without excessive
toxicity. It has also been possible to combine weekly pacli-
taxel with carboplatin.17 Favorable efficacy with this combi-
nation was noted by a phase II study that was restricted to the
elderly and patients with poor performance status.18 In an-
other phase II study, an attenuated dose of paclitaxel was
administered to elderly patients in combination with carbo-
platin. This regimen resulted in a response rate of 40% and a
median time to progression of 5.5 months.19
In our randomized phase II study that evaluated three
different weekly schedules of paclitaxel in combination with
carboplatin for patients with previously untreated advanced
NSCLC,12 the regimen with the best therapeutic index was
weekly paclitaxel (100 mg/m2 administered for 3 of 4 weeks)
in combination with carboplatin (AUC  6 mg/ml/min every
4 weeks). The subgroup analysis described in this article was
derived from this randomized phase II study.12 The propor-
tion of elderly patients included in this study is higher than
that in some of the recently reported clinical trials in ad-
vanced NSCLC.6,20 Because age was not a stratification
factor, there were minor differences in the distribution of
elderly patients between the three arms of the study. There
was a disproportionately higher representation of elderly
patients with a PS of 2 in arm 2 of the study. This could be
another contributory factor to the inferior survival noted with
this treatment arm. Another limitation of our analysis is the
lack of information regarding comorbid illness. Efficacy of
chemotherapy in the elderly cohort was comparable to the
70 years cohort in all three arms of the study. The higher
TABLE 2. Efficacy
Arm 1 Arm 2 Arm 3
>70 Yr <70 Yr >70 Yr <70 Yr >70 Yr <70 Yr
Median survival (mo) 11.3 11.2 6.0 7.7 14.4 9.1
1-yr survival rate (%) 50 46 19 35 52 38
2-yr survival rate (%) 23 11 6 11 38 14
Time to progression (mo) 7.2 6.9 5.3 4.2 8.6 6.0
S. Ramalingam et al. Journal of Thoracic Oncology • Volume 1, Number 3, March 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer242
degree of neutropenia seen in the elderly cohort is consistent
with data from other retrospective comparisons between el-
derly and younger patients with advanced NSCLC.13,14 The
lower incidence of neuropathy with the weekly regimen
makes this a more appealing option for the treatment of
elderly NSCLC patients. However, such an interpretation is
limited by the retrospective nature of this analysis. Further-
more, selection of elderly patients to clinical trials is likely to
be associated with an inherent bias.21 Therefore, the data
from elderly patients who participate in clinical trials may not
entirely apply to all elderly individuals. Even elderly-specific
clinical trials may be associated with such a selection bias.
Careful consideration of comorbid illness, functional status,
and performance status are critical before treatment decisions
are made for elderly patients.
Furthermore, no formal statistical analysis was per-
formed in our report to compare the differences in response or
toxicity, because the numbers are too small to detect a
statistical difference. It is our belief that the weekly regimen
is safe and efficacious in elderly patients and therefore war-
rants evaluation in prospective studies for elderly NSCLC
patients. The findings of this analysis are supported by the
results of our phase III study that compared the weekly
regimen (arm 1 of the study reported here) with the standard
3-weekly regimen of carboplatin-paclitaxel. The study dem-
onstrated comparable efficacy and a favorable nonhemato-
logic toxicity profile with the weekly regimen. In the elderly
subset of patients, the weekly regimen was associated with a
numerically higher response rate and survival, although the
differences did not reach significance. The nonhematologic
toxicity profile also favored the weekly regimen in the elderly
group.22 On the basis of this, the weekly regimen may also be
more suited to serve as the platform for incorporation of
molecularly targeted agents for the treatment of elderly
NSCLC patients. Considered together, the results of our
analysis add to the growing body of literature that elderly
patients with advanced NSCLC tolerate combination chemo-
therapy as well as younger patients and derive similar benefit.
As NSCLC increasingly becomes a disease of the
elderly, it is important to develop elderly-specific clinical
trials in the future. Efforts should also be undertaken to
improve accrual of elderly patients to clinical trials in
NSCLC, which will increase the applicability of clinical trial
data to elderly patients in routine practice. Another subset of
patients who have not been studied in clinical trials is the
octogenarians. In the ECOG 1594 trial, only nine patients
were older than 80 years. Prospective studies are necessary to
define the role of chemotherapy and to identify optimal
therapy for advanced NSCLC in the very elderly.
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